Valuation: Norda ASA

Market Cap 51Cr 5.52Cr 4.92Cr 4.5Cr 4.1Cr 7.73Cr 521.94Cr 7.94Cr 54Cr 22Cr 276.42Cr 21Cr 20Cr 872.24Cr P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 26Cr 2.85Cr 2.54Cr 2.32Cr 2.11Cr 3.98Cr 268.87Cr 4.09Cr 28Cr 11Cr 142.39Cr 11Cr 10Cr 449.32Cr EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day+1.06%
1 month+1.06%
3 months-0.46%
6 months+1.06%
Current year-14.00%
1 month 86
Extreme 86
86
Current year 81
Extreme 81
86.4
1 year 81
Extreme 81
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 08/04/2013
Director TitleAgeSince
Chairman 54 31/01/2014
Director/Board Member 68 20/06/2013
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.06%-.--%+6.17%+109.76% 4.76Cr
+3.80%+8.47%+64.65%+77.70% 6.69TCr
+1.63%+6.76%+24.52%+104.31% 5.65TCr
+0.07%+2.39%+11.12%+75.17% 5.72TCr
-0.07%-3.94%+25.74%+33.17% 4.35TCr
-9.40%-4.18%+207.25%+746.43% 4.28TCr
+2.80%+5.03%+21.43%+98.97% 4.3TCr
+1.59%-4.04%+97.66%+81.57% 3.21TCr
+7.50%+13.28%+28.05%+64.46% 3.4TCr
-2.40%-3.68%-42.49%+350.84% 2.41TCr
Average +0.67%+3.69%+44.41%+174.24% 4TCr
Weighted average by Cap. +0.80%+3.91%+50.78%+165.74%

Financials

2023 2024
Net sales 8.69Cr 93.55L 83.36L 76.25L 69.44L 1.31Cr 88Cr 1.34Cr 9.16Cr 3.66Cr 47Cr 3.51Cr 3.44Cr 147.74Cr 37Cr 4Cr 3.57Cr 3.26Cr 2.97Cr 5.6Cr 378.21Cr 5.75Cr 39Cr 16Cr 200.3Cr 15Cr 15Cr 632.04Cr
Net income 3.12Cr 33.55L 29.9L 27.35L 24.9L 46.94L 32Cr 48.21L 3.29Cr 1.31Cr 17Cr 1.26Cr 1.23Cr 53Cr 13Cr 1.36Cr 1.21Cr 1.1Cr 1.01Cr 1.9Cr 128.1Cr 1.95Cr 13Cr 5.31Cr 68Cr 5.09Cr 4.98Cr 214.07Cr
Net Debt -31Cr -3.35Cr -2.99Cr -2.73Cr -2.49Cr -4.69Cr -316.56Cr -4.81Cr -33Cr -13Cr -167.65Cr -13Cr -12Cr -529.02Cr -25Cr -2.68Cr -2.39Cr -2.18Cr -1.99Cr -3.75Cr -253.07Cr -3.85Cr -26Cr -10Cr -134.02Cr -10Cr -9.84Cr -422.92Cr
Projected Income Statement - Annual - Norda ASA
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
  1. Stock Market
  2. Stocks
  3. NORD Stock